Moreover, E2 pretreatment decreases basal phosphorylation of both ERK1 and ERK2 in the non-ischemic hemisphere and prevents ischemia-induced phosphorylation and activation of ERK1/2 in the ischemic hemisphere, which is consistent with findings by Xiao et al. [32]. The gene discussed is MAPK3; the disease is ischemia.